Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: Disclosed are substituted xanthines of general formula wherein R1 to R4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention broadly includes a screen assembly including a U-shaped channel, a plurality of channels, and a plurality of retainer clips. Each channel in the plurality of channels includes respective first and second walls forming an L-shape and a respective third wall hingedly connected to the respective first wall. The respective first, second, and third walls form a U-shape when the respective third wall is in a closed position. The plurality of channels are arranged to receive a screen frame when the respective third wall is in an open position and the plurality of channel elements is arranged to restrain the screen frame when the respective third wall is in the closed position. The plurality of retainer clips is arranged to releasably engage the plurality of channels to maintain the respective third wall in the closed position.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a core of non-crystalline drug and surface stabilizers consisting of a phospholipid and a bile salt.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, ethylcellulose, and a bile salt.

Abstract: Disclosed are substituted xanthines of general formula wherein R1 to R4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and an enteric polymer, and casein.

Abstract: The present invention is directed to the automatic configuration of portal composite applications.

Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and R1 to R4 are defined as in claim 1, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: A predetermined business task of a composite application can be fulfilled. The composite application can include a set of components. The composite application is instantiated by a template means and a predefined collaborative context module controls the interaction of the set of components during the runtime of the composite application. A set of components fulfilling individual services on individual different server systems is leveraged by the composite application. During the instantiation of the composite application from a template, the referenced components (as types) are instantiated leading to runtime instances of these components. The interaction of the different components is controlled on individual different server systems utilizing a primary context module.

Abstract: The invention relates to new purine derivatives of general formula wherein R1 to R4 are defined as in the claims, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.

Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and R1 to R4 are defined as in claim 1, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted xanthines of general formula the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to the field of network portals and in particular to a method and system for exchanging data between components of one or more composite applications implemented on a portal server, wherein the components are programmed independently from each other. An embodiment of the invention includes: automatically intercepting I/O data being input or output respectively to or from the components or a browser; extracting data objects from the I/O data; determining for a source component, which of the data objects match input requirements of which other potential target components; selecting matching data objects for a matching target component; and transferring the matching data objects to the matching target component.

Abstract: Compounds of formula (I) wherein R1 to R4 are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation, or calcitonin-induced osteoporosis using these compounds.

Abstract: Embodiments of systems and methods provide deployable cellular telecommunication base stations capable of sending, receiving, and extending telephone calls in areas where commercial cellular communications are unavailable. The deployable base station can send and receive cellular telephone calls via cellular communication transceivers, and relay such calls to a distant teleport via a satellite communication link. The deployable base station includes routers for encoding voice calls in voice-over IP data format and for routing calls via the satellite communication link. The deployable base station may also include land mobile radio (LMR) communication interoperability circuits to enable LMR communications to be relayed to a distant teleport. At the teleport, received communications can be routed via a public switched telephone network to an intended receiver to enable telephone communications with the global commercial network from areas lacking commercial cellular communications.

Abstract: Disclosed are substituted xanthines of general formula wherein R1 to R4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: Compounds of formula (I) wherein R1 is a phenylcarbonylmethyl group wherein the phenyl moiety is substituted, and R2 to R4 are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis using these compounds.